[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645031":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":57,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":26,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":80,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Pak Emirates Military Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral itraconazol 200mg","ACTIVE_COMPARATOR","Participants receive oral itraconazole according to the study protocol for the treatment of tinea corporis\u002Fcruris. Clinical and mycological responses are assessed during follow-up.",[13],"Drug: Itraconazole (200 mg)",{"label":15,"type":16,"description":17,"interventionNames":18},"Itraconazole Plus Isotretinoin","EXPERIMENTAL","Participants receive oral itraconazole in combination with low-dose oral isotretinoin according to the study protocol for the treatment of tinea corporis\u002Fcruris. Clinical and mycological responses are assessed during follow-up.",[13,19],"Drug: ISOtretinoin 20 MG",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Itraconazole (200 mg)","Oral itraconazole 200 mg daily administered to adult patients with tinea corporis\u002Fcruris. Treatment is continued according to the study protocol, and participants are monitored for clinical improvement, mycological cure, adverse events, and recurrence.",[15,9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"ISOtretinoin 20 MG","Oral isotretinoin 20 mg daily administered in combination with oral itraconazole 200 mg daily to adult patients with tinea corporis\u002Fcruris. Participants are monitored for treatment response, mycological cure, adverse events, and recurrence according to the study protocol.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Maria Ahmed, MBBS","CONTACT","+9236666630","mariafazeelkhan@gmail.com",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"PakEmirates","Rawalpindi","Punjab Province","46000","Pakistan","PK",{"type":46,"coordinates":47},"Point",[48,49],73.0479,33.59733,{"lat":49,"lon":48},[52,55],{"name":53,"role":34,"phone":54,"phoneExt":26,"email":36},"Moizza Tahir, MBBS","+923000113959",{"name":33,"role":56,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Maria Ahmed","Resident dermatology","100645031","phase-4-comparison-of-itraconazole-with-itraconazole-and-isotretinoin-in-the-treatment-duration-safety-a-n-d-cure-rate-in-adult-patients-of-tinea-corporis-cruris-a-randomised-controlled-trail-100645031",false,"NCT07675239","Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety a n d Cure Rate in Adult Patients of Tinea Corporis\u002F Cruris-A Randomised Controlled Trail","Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety, and Cure Rate in Adult Patients With Tinea Corporis\u002FCruris: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Al newly diagnosed cases with typical tinea lesion involving at least 5% body surface area (BSA) with no nail\u002Fscalp\u002Fpalm\u002Fsole involvement and no history of intake of any oral antifungal in the preceding 4 weeks or of a topical antifungal\u002Fsteroid in the preceding 2 weeks. Presenting to the outpatient department or the emergency department of PEMH or CMH will be included in the study.\n\nExclusion Criteria:\n\n* 1\\. Patients with chronic liver and renal diseases. 2. Patients with ischaemic heart diseases. 3. Patients with hyperlipidemia. 4. 5. Those on chronic immunosuppressive therapy. Pregnant and lactating women and females of reproductive age. 6. Elderly patients above 75 years 7. Patient who had taken oral antifungal in the preceding 4 weeks or of a topical antifungal\u002Fsteroid in the preceding 2 weeks","ALL","75 Years",{"count":70,"type":71},60,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","Tinea corporis and tinea cruris are common superficial fungal infections that have become increasingly difficult to treat because of prolonged disease duration, frequent recurrences, and suboptimal response to standard antifungal therapy. Itraconazole is widely used for the treatment of dermatophytosis; however, treatment failures and relapses remain a significant concern. Isotretinoin has been proposed as an adjuvant therapy because of its effects on epidermal differentiation, keratinization, and follicular function, which may enhance antifungal penetration and improve treatment outcomes.\n\nThis randomized controlled trial aims to compare itraconazole monotherapy with a combination of itraconazole and isotretinoin in adult patients with tinea corporis and\u002For tinea cruris. The study will evaluate treatment duration, cure rate, and safety profile of both regimens. The findings may provide evidence regarding the potential benefit of adding isotretinoin to conventional antifungal therapy and help optimize management strategies for adult patients with dermatophytosis.",[77],"Tinea Corporis",[79],"Tinea, itraconazol, isotretinoin","NOT_YET_RECRUITING","2026-06-23",{"date":83,"type":84},"2026-06-30","ACTUAL",{"date":86,"type":71},"2026-10-01",{"date":88,"type":71},"2027-03-01",{"name":5,"class":6},1]